This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Jun 21, 2024
•
11 min read
Sapreta Therapeutics lands key DMD label expansion, Gilead's twice-yearly HIV prevention med scores 100% efficacy, iOnctura raises $86M, Takeda drops $230M on a facility expansion, and Bora makes US-based sterile manufacturing moves
Jun 19, 2024
8 min read
GSK has a double Ph3 win, Marea Therapeutics launches with $190M to go after remnant cholesterol, Hikma buys multiple assets and sites from Xeliia Pharmaceuticals, and Sanofi and Roche both sign big drug development partnership
Jun 18, 2024
9 min read
AstraZeneca & Merck both land FDA approvals for endometrial cancer, Takeda's epilepsy bet is up in flames, Merck lands a historic vaccine approval, and a BioNTech and MediLink Therapeutics ADC gets an FDA partial hold
Jun 17, 2024
Vertex releases positive long term gene therapy data, Vaxart lands a big BARDA contract, AI drug discovery debuts on Hong Kong stock exchange, Kyverna has a rough week due to autoimmune data and 100% of something for two cancer biotechs
Jun 15, 2024
🧬 Winners, Losers, and Upcoming Earnings Calls
Jun 14, 2024
Pfizer's DMD hopes shattered in Ph3 (while also planning for 8 blockbusters by 2030), while JP Morgan closes $500M biotech fund, a new antibody player launches with $168M, and Eli Lilly gets an upgrade (from accelerated to full approval)
Jun 13, 2024
10 min read
BMS still has an M&A appetite, Ultragenyx has some bone-building Ph2/3 results, Eli Lilly's Alzheimer's approval could be good news for rivals Biogen and Eisai too, Foresite Capital raises a $900M life science fund, and Pfizer signs a discovery pact with ProFound Therapeutics in search of the next great obesity med
Jun 12, 2024
Syntis Bio to take on GLP-1 giants, Ipsen's new FDA approval, an ADC and an "ADC-like" company both raise millions, cancer patient groups like AstraZeneca, and Pfizer takes an M&A break
Jun 11, 2024
Eli Lilly gets full support from FDA advisory panel, GSK's RSV vaccine gets a label expansion, Moderna’s flu/covid combo passes Ph3, Amber Therapeutics raises $100M, Alumis plans an IPO, and the FDA gets curious about AI
Jun 10, 2024
Geron lands first FDA approval after 34 years, Abbvie & Calico join FDA rare disease pilot, Rapport Therapeutics upsized IPO to $154M, and Eli Lilly could secure Alzheimer's throne
Jun 8, 2024
6 min read
Jun 7, 2024
Boehringer & Zealand Pharma Ph2 NASH data "unintentionally" published early, Seres Therapeutics sells a commercial asset to stay afloat, Abbvie's $10.1B ImmunoGen acquisition delivers Ph2 win, Nucleus RadioPharma fundraise, and Structure Therapeutics hopes to ride the data wave to a $476M stock sale
